Last reviewed · How we verify
Pagitane (CYCRIMINE)
Pagitane (generic name: CYCRIMINE) is a Small molecule drug developed by Eli Lilly. It is currently FDA-approved (first approved 1982) for Parkinson's disease.
At a glance
| Generic name | CYCRIMINE |
|---|---|
| Sponsor | Eli Lilly |
| Target | Muscarinic acetylcholine receptor M1 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
- Parkinson's disease
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pagitane CI brief — competitive landscape report
- Pagitane updates RSS · CI watch RSS
- Eli Lilly portfolio CI
Frequently asked questions about Pagitane
What is Pagitane?
Pagitane (CYCRIMINE) is a Small molecule drug developed by Eli Lilly, indicated for Parkinson's disease.
What is Pagitane used for?
Pagitane is indicated for Parkinson's disease.
Who makes Pagitane?
Pagitane is developed and marketed by Eli Lilly (see full Eli Lilly pipeline at /company/eli-lilly).
What is the generic name of Pagitane?
CYCRIMINE is the generic (nonproprietary) name of Pagitane.
When was Pagitane approved?
Pagitane was first approved on 1982.
What development phase is Pagitane in?
Pagitane is FDA-approved (marketed).
What does Pagitane target?
Pagitane targets Muscarinic acetylcholine receptor M1.
Related
- Target: All drugs targeting Muscarinic acetylcholine receptor M1
- Manufacturer: Eli Lilly — full pipeline
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Parkinson's disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing